TL;DR: Moderna’s mRNA cancer vaccine, developed with Merck as mRNA-4157 (V940), cut recurrence or death by 49% versus Keytruda alone in high-risk melanoma at 18 months, and by 62% at 3 years in updated Phase 2b data. It is not yet FDA-approved; a confirmatory Phase 3 trial is fully enrolled, so these results are promising but preliminary.
Feature Highlights
The vaccine is not a preventive shot like a flu vaccine. It is a personalized therapy: researchers sequence a patient’s tumor, identify up to 34 unique neoantigens, and manufacture an mRNA cocktail tailored to that specific cancer. The goal is to train the immune system to hunt down residual cancer cells after surgery.
If you want to dig deeper, check out our guide on **Gut Microbiome Tests: Guide to Personalized Diets**
*(53 .
In the Phase 2b KEYNOTE-942 trial, 157 patients with completely resected high-risk melanoma received either the vaccine plus pembrolizumab (Keytruda) or pembrolizumab alone. The combination reduced the risk of recurrence or death by 49% at 18 months, and updated three-year data showed a 62% reduction in recurrence or death. The vaccine also showed a manageable safety profile, with fatigue, injection-site pain, and flu-like symptoms being the most common side effects.
How It Compares
Traditional cancer vaccines have largely failed over the past two decades, often because they targeted a single antigen and couldn’t keep pace with tumor mutations. Moderna’s approach is different: it uses mRNA technology, the same platform behind its COVID-19 vaccine, which allows rapid, personalized manufacturing. Compared with checkpoint inhibitors alone, which work in only a subset of patients, the combination appears to broaden and deepen immune responses.
It is also worth comparing with BioNTech’s competing mRNA cancer vaccine, which has shown similar early promise in pancreatic and colorectal cancers. Moderna’s melanoma data is further along, but neither product is approved yet.
What This Means for Patients
If you or a loved one has high-risk melanoma, this is not yet a standard option. Enrollment in the Phase 3 trial is closed, but results are expected in the next few years. For now, the best path remains surgery, immunotherapy, and clinical trial participation where available. Ask your oncologist whether any mRNA cancer vaccine trials are recruiting for your cancer type.
FAQ
Q: Is Moderna’s mRNA cancer vaccine available to the public?
A: No. It is still investigational and only available through clinical trials. The FDA has not approved it for any cancer.
Q: Does the vaccine prevent cancer like a traditional vaccine?
A: No. It is a treatment vaccine given after surgery to prevent recurrence, not a preventive shot for healthy people.
Q: What cancers is it being tested in?
A: The furthest data is in high-risk melanoma, but trials are also exploring it in lung, kidney, and other solid tumors.
Leave a Reply